Jointly provided by
|
This activity is supported by independent educational grants from Bristol Myers Squibb and Merck & Co., Inc.
|
|
Learn About
|
- Latest trial results on checkpoint inhibitors and CAR-T therapies
- MOA of novel immuno-oncology agents
- Key outcome measures and payment models in immuno-oncology
|
Expert Faculty Presenters
|
|
|
|
|
Yung Lyou, MD, PhD
Oncologist
Assistant Clinical Professor, Department of Medical Oncology
City of Hope
|
|
Edmund Pezalla, MD, MPH
CEO
Enlightenment Bioconsult, LLC
|
|
|
|
Who Should Attend?
|
This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses and other managed health care professionals.
|
|
Statement of Need/Program Overview
|
The advent and rapid escalation of targeted cancer therapies has led to the emergence of sophisticated immuno-oncology agents. However, the historically high cost of these agents has compelled payers to initiate strategies to control utilization and manage costs. Because of the explosive growth of this category and their corresponding budgetary impact, healthcare decision makers (HCDMs) and managed care professionals require education on the principles of immuno-oncology and the mechanisms of action behind these novel treatments. Furthermore, given increased focus on value-based benefit design, utilization management, and payer-led clinical interventions to address shortfalls in oncology practice, managed care stakeholders also have a need for information to effectively address the evolving paradigm of cancer treatment. This webcast will provide HCDMs and managed care professionals with the required education on the principles of immuno-oncology and the mechanisms of action behind these novel treatments.
|
|
Educational Objectives
|
At the conclusion of this activity, participants should be able to demonstrate improved ability to:
- Characterize the role of the immune system in immunosurveillance and elimination of malignant cell lines
- Explain the mechanisms of action of novel immuno-oncology agents such as PD-1 and PD-L1 inhibitors and CAR-T therapies
- Describe key outcomes measures in immuno-oncology and the importance of cumulative assessment of outcomes
- Apply comprehensive analyses of emerging clinical trial data for checkpoint inhibitors and CAR-T therapies
- Illustrate current and proposed payer initiatives for the funding and management of checkpoint inhibitors and CAR-T therapies
|
|
Agenda
|
Date and Time
Monday, June 15, 2020
12:30 PM - 2:00 PM ET
|
Opening Comments/Overview
Edmund Pezalla, MD, MPH
|
Clinical Update on the Evolving Immuno-Oncology Treatment Paradigm
Yung Lyou, MD, PhD
|
Evidence-based Decision Making in a Cost Conscience Environment
Edmund Pezalla, MD, MPH
|
Medical and Pharmacy Management Strategies to Enhance Outcomes Requiring Treatment with Immuno-Oncology Agents
Edmund Pezalla, MD, MPH
|
Audience Q&A Session
|
|
Key Takeaways and Closing Comments
|
Adjournment
|
|
Accreditation Information
|
|
Joint Accreditation Statement |
 |
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
|
|
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008162-9999-20-2107-L01-P
Type of Activity: Application
|
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.
|
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.
Fee Information
There is no fee for this educational activity.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Fee Information
No additional fee is required to attend this CME/CPE/CNE activity.
If you have any questions, please call (215) 619-8812 or email info@impactedu.net.
|
|
